CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects. - Wikidata - awgldk - TriplyDB

CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects.

CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects.

http://www.wikidata.org/entity/Q36407301

about

Alzheimer's disease--subcortical vascular disease spectrum in a hospital-based setting: Overview of results from the Gothenburg MCI and dementia studies Neuropathologic correlates of cognition in a population-based sample.Cross-sectional and longitudinal relationships between cerebrospinal fluid biomarkers and cognitive function in people without cognitive impairment from across the adult life span.Understanding cognitive deficits in Alzheimer's disease based on neuroimaging findings A focus on structural brain imaging in the Alzheimer's disease neuroimaging initiative Tensor Regression with Applications in Neuroimaging Data Analysis.Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.Apolipoprotein E epsilon4 does not modulate amyloid-β-associated neurodegeneration in preclinical Alzheimer disease.Longitudinal measures of cholinergic forebrain atrophy in the transition from healthy aging to Alzheimer's disease.Cerebral Blood Flow and Amyloid-β Interact to Affect Memory Performance in Cognitively Normal Older Adults.Amyloid burden, neuronal function, and cognitive decline in middle-aged adults at risk for Alzheimer's disease Should we disclose amyloid imaging results to cognitively normal individuals?Plasma based markers of [11C] PiB-PET brain amyloid burden.Mapping 3-year changes in gray matter and metabolism in Aβ-positive nondemented subjects.Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer's disease Pittsburgh compound B retention and progression of cognitive status--a meta-analysis.Brain structure and function as mediators of the effects of amyloid on memory.Brain Amyloid Deposition and Longitudinal Cognitive Decline in Nondemented Older Subjects: Results from a Multi-Ethnic Population.Rich club analysis in the Alzheimer's disease connectome reveals a relatively undisturbed structural core network.Amyloid PET in European and North American cohorts; and exploring age as a limit to clinical use of amyloid imaging.Florbetapir positron emission tomography and cerebrospinal fluid biomarkers.Age and amyloid effects on human central nervous system amyloid-beta kinetics.Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease Alzheimer Disease Cerebrospinal Fluid Biomarkers Moderate Baseline Differences and Predict Longitudinal Change in Attentional Control and Episodic Memory Composites in the Adult Children Study.Postmortem Pittsburgh Compound B (PiB) binding increases with Alzheimer's disease progression.Maternal family history is associated with Alzheimer's disease biomarkers Meta-analysis of amyloid-cognition relations in cognitively normal older adults Cognitive reserve associated with FDG-PET in preclinical Alzheimer disease Modular reorganization of brain resting state networks and its independent validation in Alzheimer's disease patients.Is amyloid-β harmful to the brain? Insights from human imaging studies Amyloid deposition, hypometabolism, and longitudinal cognitive decline Cognitive impairment and decline in cognitively normal older adults with high amyloid-β: A meta-analysis.Clinical applications of neuroimaging in patients with Alzheimer's disease: a review from the Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012.Cognitive and neural signatures of the APOE E4 allele in mid-aged adults.Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer's disease.[Formula: see text]Practice effects and longitudinal cognitive change in clinically normal older adults differ by Alzheimer imaging biomarker status.Moderating effects of sex on the impact of diagnosis and amyloid positivity on verbal memory and hippocampal volume.Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum.Age effects on cortical thickness in cognitively normal elderly individuals.White Matter Hyperintensities Potentiate Hippocampal Volume Reduction in Non-Demented Older Individuals with Abnormal Amyloid-β.

P2860

Q26798325-269BB834-5FC4-4BD1-B94A-4F12E8323D96 Q30445117-9231F690-C79E-4D5F-B258-70B928E82101 Q30580439-5CF25577-F7E9-433E-AF90-267922D684D1 Q30666527-BEDB3C17-68F9-442D-A103-92F2F80CBFD4 Q30724134-8DA9B0C5-CFE3-43AE-80AD-DF13F51C7B9A Q30813361-D7049C25-89AB-4A88-A90E-70C721F1FEBB Q33604453-E888EE99-0C1E-45CD-BB84-3C24C21E07BA Q33699415-55D645C8-86D0-4B5D-B455-1770CFFCD85D Q33759008-5BFC5E01-FBEB-45F6-90FC-3C7DDEB85B38 Q33775095-A0E0E7C6-0D07-4871-B76A-E8C3CF1CD02B Q33920450-A8D47701-5E52-4BF4-AE4B-35543D3E1864 Q34286140-05570DBC-8E58-4C34-ACE1-2ACAFEFD269E Q34427001-6C503F10-CB96-47AA-9539-D7DD74214830 Q34498348-AEE37262-885D-4110-B143-5852DDA5A6C2 Q35106997-E0FE4196-BDC0-4BBE-AF45-62DE1ABAE914 Q35115487-86120598-AC16-4000-82DE-02DBF4096B9D Q35211063-DC2BC966-B2D4-412B-8F0E-3647CDB5A421 Q35722468-078C6A0B-0749-4F2C-908C-700F59278E7F Q35858721-3E568ED5-13AF-48BF-9B4F-44646BC8CA85 Q35905536-BBE6D8C4-EC18-4F2C-8EDC-D87E77865C62 Q35981544-9B531B2B-50DC-4F1A-AFF9-2A334990C99D Q35987665-49762A1D-273D-4C02-A2C7-51D2B7827B10 Q36005633-8D01616E-E976-4ACB-AEA2-06EFA1FD5BFA Q36175421-006C40C5-FDCC-4537-8B40-B652D6921980 Q36713678-9E4F968B-E06A-4C39-8D5B-0BF28D4BF6C3 Q36717013-E1C882F4-9426-40F0-AA4D-EDF1F6206130 Q36850873-A7960A71-E216-44D5-A513-F74B9EEB9611 Q36953075-D8FD3FAC-3A16-42B8-80CC-380BA108591A Q37084021-78638B1B-CA87-49E8-84FB-D53661425FF7 Q37188315-4EFB58AB-BAA6-4ED4-BAB1-8DF0199D9CE5 Q37207254-0543EB38-EAD8-468A-85F3-473385931707 Q37650253-31C1EA24-42D0-4179-99F2-E6854CED83B3 Q37693470-F5F3E717-A9A1-406E-B857-CD0C42A3AFE5 Q37725764-FACD9C60-EDE8-429F-98B4-CCA996EB749A Q38797428-44E0C420-11E6-4974-9EB1-BC0A22A52055 Q40547789-77CEFD4E-B597-4C73-957A-D176627D40FB Q41151211-0699B12A-1996-4B4B-9D79-4F0339367705 Q41654319-5C97A411-BFAA-4435-9E73-03D0195139EF Q42157422-10340E73-A477-4F2F-880C-38BA1CF91B4A Q47930258-90413040-D4AA-4D56-B7EE-DA82D4E81B00

P2860

CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects.

http://www.wikidata.org/entity/Q36407301

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

CSF biomarker and PIB-PET-deri ...... anges in nondemented subjects.

@ast

CSF biomarker and PIB-PET-deri ...... anges in nondemented subjects.

@en

type

label

CSF biomarker and PIB-PET-deri ...... anges in nondemented subjects.

@ast

CSF biomarker and PIB-PET-deri ...... anges in nondemented subjects.

@en

prefLabel

CSF biomarker and PIB-PET-deri ...... anges in nondemented subjects.

@ast

CSF biomarker and PIB-PET-deri ...... anges in nondemented subjects.

@en

P1433

Q36407301-1C49B2BF-7608-4F59-8113-5EF77892C16F

P1476

Q36407301-67A5BF4B-948F-455D-9C10-6AC3D56EF91F

P2093

Q36407301-07866006-A0C4-424F-A92E-1B7218BBE9B5

Q36407301-25250CD0-9035-42DE-BEC5-64BAFF150258

Q36407301-89663281-5EA1-4BF7-AF7A-367EF55CC9D3

Q36407301-C1872499-229E-4877-8653-58FF449D1233

Q36407301-CBF1293D-CFA6-4554-B67D-BEF0BDF0F4BD

P2860

Q36407301-078E1BCE-0285-4DF1-A4B6-0D6F1470E3BA

Q36407301-0969C3B3-FB7F-43EB-B326-461145054307

Q36407301-0F0F8120-ACC4-4289-9ABE-7EA0B1991120

Q36407301-0F4FA8B3-62E3-4C0F-830A-F618FE2CEC97

Q36407301-11750ED8-4F76-41B7-AE5E-2DC274EF83DC

Q36407301-1A1B9173-3DB1-4DD2-97EA-50EF4EE04670

Q36407301-1CF10759-1C42-44F4-93AB-3D9A7CF21283

Q36407301-2BA2FBDC-6076-4F09-9F9B-69AB5E6C8C1F

Q36407301-2C202D33-7C54-4CD6-9883-2768E30C5A52

Q36407301-2E412447-DE1C-4A91-B719-3544FBA3DCB1

P304

Q36407301-DB8C79F5-BA6D-4F4D-B8CD-CDACF0BB8C54

P31

Q36407301-015006F2-D43F-4A2D-B078-FFD52ACB67F3

P356

Q36407301-1087901E-303C-487D-B6C7-D597B319DE6D

P433

Q36407301-A5A2EBE5-542D-47F2-9C6F-B7499AB12038

P478

Q36407301-833B0808-B391-4F92-AD27-93106803E950

P50

Q36407301-24556FA3-45EF-42AE-A6DD-0B114D4BDB92

Q36407301-7013BB80-6A53-48B7-8A89-5F6E0F08FD3E

Q36407301-73184804-BA9A-4CDA-BE10-35C06582E911

Q36407301-B5D7CCC0-8618-4A71-A751-1B5B5205F551

Q36407301-EA7E9BBB-D121-42ED-9543-EB74CD692D21

P577

Q36407301-A49160B3-F220-4C0E-8126-D8D95311FA4A

P5875

Q36407301-C9D9401D-F173-466B-AE25-0F594BC1E10A

P698

Q36407301-71AB56B7-36B1-43A4-BF96-AEE0E7F78481

P921

Q36407301-FC32F728-A3B2-48A9-AF30-1F4205064D63

P932

Q36407301-7D3FD693-8CFE-4F13-9442-876112F007F4

P356

P1433

Cerebral Cortex

P1476

CSF biomarker and PIB-PET-deri ...... anges in nondemented subjects.

@en

P2093

Leslie Shaw

http://www.w3.org/2001/XMLSchema#string

Michael Ewers

http://www.w3.org/2001/XMLSchema#string

Norbert Schuff

http://www.w3.org/2001/XMLSchema#string

Philip Insel

http://www.w3.org/2001/XMLSchema#string

William J Jagust

http://www.w3.org/2001/XMLSchema#string

P2860

Neural correlates of Alzheimer's disease and mild cognitive impairment: a systematic and quantitative meta-analysis involving 1351 patients

Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people

The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods.

11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

Neuropathological stageing of Alzheimer-related changes

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

Cortical Surface-Based Analysis

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

Remembering familiar people: the posterior cingulate cortex and autobiographical memory retrieval

P304

1993-2004

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CERCOR/BHR271

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

Alzheimer's Disease Neuroimaging Initiative

Ronald C. Petersen

Michael W. Weiner

John Q. Trojanowski

P577

2011-10-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51753506

http://www.w3.org/2001/XMLSchema#string

P698

22038908

http://www.w3.org/2001/XMLSchema#string

P921

P932

3500862

http://www.w3.org/2001/XMLSchema#string